IMCR241018C35000
- 0.20
- 0.000.00%
Immunocore Newsroom
Barclays Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $66
Barclays Gives a Buy Rating to Immunocore Holdings (IMCR)
A Quick Look at Today's Ratings for Immunocore(IMCR.US), With a Forecast Between $78 to $100
Immunocore Hldgs Analyst Ratings
TD Cowen Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $90
Capital One Financial Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $90
Mizuho Securities Maintains Immunocore(IMCR.US) With Buy Rating, Announces Target Price $72
Buy Rating Affirmed for Immunocore Holdings on Promising Brenetafusp Prospects and Strong Company Fundamentals
Barclays Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $66
The Latest Analyst Ratings For Immunocore Hldgs
H.C. Wainwright Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $100
Immunocore Holdings Price Target Maintained With a $100.00/Share by HC Wainwright & Co.
Goldman Sachs Maintains Immunocore(IMCR.US) With Buy Rating
Mizuho Securities Maintains Immunocore(IMCR.US) With Buy Rating
Immunocore Holdings: Outperform Rating With Promising Sales Growth and Strategic Advantages
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Natera (NTRA) and Disc Medicine (IRON)
Immunocore Holdings (IMCR) Gets a Buy From BTIG
Immunocore Hldgs Analyst Ratings
Immunocore Holdings: Strong Kimmtrak Sales and Promising Pipeline Merit Buy Rating
Optimistic Buy Rating on Immunocore Holdings Amid Strong Kimmtrak Sales and Promising Oncology Pipeline